| Abstract: |
The present invention relates generally to production methods, enzymes and recombinant yeast strains for the biosynthesis of clinically important prenylated polyketides of the cannabinoid family. Using readily available starting materials, heterologous enzymes are used to direct cannabinoid biosynthesis in yeast. |
| Inventor: |
Barr, Philip J. (Oakland, CA, US); Marlowe, Charles K. (Emerald Hills, CA, US); Sun, Jianping (Redwood City, CA, US) |
| Applicant: |
BayMedica, Inc. (Incline Village, NV, US) |
| Face Assignee: |
BAYMEDICA, INC. (Incline Village, NV, US) |
| Filed: |
2018-05-10 |
| Issued: |
2020-11-17 |
| Claims: |
13 |
|
US10837031
|
1. A modified recombinant yeast cell comprising: (i) a first exogenous polynucleotide that encodes an acyl-CoA synthetase that converts an aliphatic carboxylic acid to an acyl CoA thioester, wherein the acyl-CoA synthetase polypeptide comprises an amino acid sequence having at least 95% identity to SEP ID NO: 1, (ii) a second exogenous polynucleotide that encodes an olivetolic acid synthase polypeptide comprising an amino acid sequence having at least 95% identity to SEP ID NO:4, (iii) and a third exogenous polynucleotide that encodes a 2-alkyl-4,6-dihydroxybenzoic acid cyclase polypeptide comprising an amino acid sequence having at least 95% identity to SEP ID NO:5, 6, or 7, wherein the second and third exogenous polynucleotide are expressed as a dicistronic mRNA.
(7)
(0)
|
|
